Skip to content

ELI LILLY & Co

LLY

Latest QuantConomy context for LLY: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class
stock
Primary venue
NYSE
Recent signals
3
SEC filings
0
Asset profile

ELI LILLY & Co

Eli Lilly and Company is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Eli Lilly, the company is a global leader in the discovery, development, manufacture, and sale of pharmaceutical products. Its key therapeutic areas include neuroscience, cardiometabolic, cancer, and immunology, with notable products such as Verzenio for cancer, Mounjaro, and various insulin treatments. Eli Lilly's products are sold in approximately 125 countries, and the company is listed on the New York Stock Exchange under the symbol LLY. As of 2024, it is ranked among the Fortune 500 and Forbes Global 2000 lists, reflecting its significant presence in the pharmaceutical industry.

Symbol
LLY
Name
ELI LILLY & Co
Coverage
3 market/data records
Sources
alphavantage alpaca fmp sec nasdaq openfigi
Latest signal rows

Recent signals for LLY

Scored rows are pulled from the same signal API used by the digests.

Signal Direction Score Observed Reason
proposed sale
large proposed sale
bearish
79
Jul 7, 07:10 PM LILLY ENDOWMENT, INC. filed Form 144 to sell LLY shares ($372.02M) - 310,000 shares - expected around 7/7/2026 - [strong bearish signal - supply pressure]
proposed sale
large proposed sale
bearish
79
Jun 26, 06:30 PM LILLY ENDOWMENT, INC. filed Form 144 to sell LLY shares ($343.95M) - 305000 shares - expected around 6/26/2026 - [strong bearish signal - supply pressure]
earnings
earnings release
neutral
40
Feb 4, 12:00 AM LLY filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-02-04. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read).

PROPOSED_SALE signals are experimental: historical Form 144 coverage is still being backfilled, so results may be sparse or empty.

EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).

Market coverage

Market Exchange Source Asset record
LLY NYSE alphavantage Lilly(Eli) & Company
LLY NYSE alpaca Eli Lilly & Co.
LLY NYSE fmp Eli Lilly and Company

Recent insider transactions

Buys, last 90d
0
Sells, last 90d
0
Rows
0

No recent Form 3, 4, or 5 insider transaction rows were returned for LLY.

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

Query LLY context like a database.

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.

No spam, no noise. Just the launch and the occasional preview.

More: All insider trades · How to read a Form 4 · API access